GlassScriptPhysician profile
Barry L Levine
NPI 1134114366
$2,386.80
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $438 · 2020: $578 · 2021: $423 · 2022: $585 · 2023: $187 · 2024: $175.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $362.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $361.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $572.07 | 2021-2023 | |
| Allergan, INC. | $436.31 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $253.24 | 2019-2022 | |
| Almatica Pharma LLC | $203.54 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $118.56 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $108.65 | 2021-2022 | |
| Neos Therapeutics, LP | $108.01 | 2020-2024 | Adzenys Xr-Odt |
| Vanda Pharmaceuticals INC. | $107.44 | 2019-2024 | Fanapt, Hetlioz |
| Jazz Pharmaceuticals INC. | $92.86 | 2019-2021 | |
| Lundbeck LLC | $90.95 | 2019-2024 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $89.27 | 2020-2022 | |
| Corium, LLC | $57.51 | 2022-2024 | Azstarys |
| Neurocrine Biosciences, INC. | $38.43 | 2024 | Ingrezza |
| Alkermes, INC. | $23.82 | 2022 | |
| Ironshore Pharmaceuticals INC. | $20.43 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $20.20 | 2022 | |
| Neuronetics, INC. | $19.29 | 2019 | |
| Alfasigma USA, INC. | $15.17 | 2021 | |
| Shire North American Group INC | $11.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barry Levine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.